Ionis Pharmaceuti…
USUSDIonis Pharmaceuticals Inc (MI:1IONS) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het Bedrijf
- Website
- ionis.com
- Beleggersrelaties
- ir.ionis.com/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- CARLSBAD, United States
- CEO
- Brett P. Monia
- Werknemers
- 1 480
- Beursgenoteerd Sinds
- 18.08.2025 (MI:1IONS)
- Uitstaande Aandelen
- Free Float
- 164.82 mln.
- Marktkapitalisatie
- 7.42 mld. USD
- Insiders
- 0.61%
- Institutionele Beleggers
- 110.5%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- XTIQ
- ISIN
- US4622221004
- LEI
- 549300SI4ZGLG0BLUZ92
- P/E
- verlies
- FCF
- −561 mln. USD
- Schuld
- 1.81 mld. USD
- Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
- NAV
Beschrijving
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| FMR, LLC | 14.82% | 24.63 mln. | 2026-06-30 |
| Capital World Investors | 13.04% | 21.67 mln. | 2026-06-30 |
| Blackrock Inc. | 6.44% | 10.7 mln. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 5.12% | 8.5 mln. | 2026-07-31 |
| Vanguard Portfolio Manag… | 4.73% | 7.86 mln. | 2026-06-30 |
| Growth Fund of America | 4.61% | 7.67 mln. | 2026-06-30 |
| Wellington Management Gr… | 4.6% | 7.65 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 7.21 mln. | 2026-06-30 |
| Two Sigma Investments, L… | 3.76% | 6.25 mln. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 3.74% | 6.21 mln. | 2026-07-31 |
| Royal Bank of Canada | 3.72% | 6.18 mln. | 2026-06-30 |
| SmallCap World Fund Inc | 3.17% | 5.26 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3% | 4.99 mln. | 2026-06-30 |
| New Economy Fund | 2.93% | 4.87 mln. | 2026-06-30 |
| State Street Corporation | 2.61% | 4.33 mln. | 2026-06-30 |
| T. Rowe Price Investment… | 2.38% | 3.96 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 3.6 mln. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.44% | 2.39 mln. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 2.08 mln. | 2026-06-30 |
| T. Rowe Price Mid-Cap Gr… | 1.2% | 2 mln. | 2026-06-30 |
| MONIA BRETT P (Chief Exe… | ≈0.15% | 245 571 | 2026-06-26 |
| BERTHELSEN SPENCER R (Di… | ≈0.1% | 161 303 | 2026-07-15 |
| HOUGEN ELIZABETH L (Chie… | ≈0.05% | 82 660 | 2026-03-17 |
| SCHNEIDER EUGENE (Office… | ≈0.05% | 77 114 | 2026-06-26 |
| BIRCHLER BRIAN (Officer) | ≈0.04% | 67 500 | 2026-04-16 |
| O'NEIL PATRICK R (Genera… | ≈0.04% | 61 470 | 2026-06-26 |
| GEARY RICHARD S (Officer… | ≈0.04% | 59 657 | 2025-11-06 |
| BAROLDI JOSEPH (Officer) | — | — | 2026-06-26 |
| BENNETT C FRANK (Officer… | — | — | 2026-07-07 |
| HAYDEN MICHAEL REUBEN (D… | — | — | 2026-07-31 |
Log in met Google